Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
Trial Summary
What is the purpose of this trial?
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways and combining it with chemotherapy before surgery may kill more tumor cells. It is not yet known which radiation therapy regimen combined with chemotherapy with or without surgery is more effective for head and neck cancer. PURPOSE: Randomized phase III trial to compare two different radiation therapy regimens combined with cisplatin with or without surgery in treating patients who have stage III or stage IV head and neck cancer.
Research Team
Phuc Felix Nguyen-Tan, MD
Principal Investigator
CHUM Hospital Notre Dame
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Accelerated fractionation radiation therapy (Radiation)
- Cisplatin (Alkylating agents)
- Conventional surgery for select patients (Surgery)
- Standard fractionation RT (Radiation)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Radiation Therapy Oncology Group
Lead Sponsor
Dr. Vivek S. Kavadi
Radiation Therapy Oncology Group
Chief Executive Officer
MD from Harvard Medical School, MBA from The Wharton School
Dr. Gita Suneja
Radiation Therapy Oncology Group
Chief Medical Officer
MD from University of Utah School of Medicine
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School
NRG Oncology
Collaborator
Stephanie Gaillard
NRG Oncology
Chief Medical Officer
MD from Johns Hopkins University
Norman Wolmark
NRG Oncology
Chief Executive Officer since 2023
MD from Harvard Medical School